FoRx Therapeutics

PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show high potency across multiple solid tumor cell lines and in vivo models, including those resistant to PARP inhibitors Presentation als

PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancersPreclinical data show high potency across multiple solid tumor cell lines and in vivo models, including those resistant to PARP inhibitorsPresentation also

PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show high potency across multiple solid tumor cell lines and in vivo models, including those resistant to PARP inhibitorsPresentation also

FoRx Therapeutics, a clinical-stage biotech developing precision oncology medicines, has closed an insider-led $50 million (CHF 40 million) Series A financing to advance its lead candidate, FORX-428, into and through Phase 1 clinical development in advanc

Basel, Switzerland, December 18, 2025 - FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor

Funding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428FORX-428 is potential new treatment option for patients whose cancers are resistant to, or have become resistant to, PARP inhibitorsInitial data expected in

Funding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428FORX-428 is potential new treatment option for patients whose cancers are resistant to, or have become resistant to, PARP inhibitorsInitial data expected in

PRN_FinancialWrapper

Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studies Trial initially taking place in the U.S., following IND clearance Initial data expected in mid-2026 from open-label Phase 1 study in advanced solid tumors Milesto

Forx Therapeutics AG has discovered new bicyclo heteroaryl poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.